In advanced dry disease, a key problem is failure of retinal pigment epithelium, often shortened to RPE. These cells help ...

Companies across the globe are diligently working toward developing novel Dry Age Macular Degeneration treatment therapies ...

An editorial published today in The New England Journal of Medicine (NEJM) writes that Science Corporation’s PRIMA implant is ...

Scientists at USC are launching a new trial to test a tiny stem cell implant that could restore vision in people with ...

The FDA granted fast track designation for CTx001, an investigational gene therapy candidate for geographic atrophy secondary ...

Ollin Biosciences has announced positive topline results from its randomized, head-to-head Phase 1b JADE clinical study ...

Medically reviewed by Christine L. Larsen, MD Key Takeaways Macular degeneration is a common eye disease, affecting more than 19 million people in the United States alone.The condition can reduce a ...

Once diagnosed, age-related macular degeneration (AMD) needs to be regularly monitored for progression both before treatment or rehabilitation is initiated (to guide the initiation decision) and ...

People with macular degeneration and other forms of central vision loss can see details like text and faces with this device.

The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the ...